Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Cannabis Science, Inc. (OTC: CBIS).

Full DD Report for CBIS

You must become a subscriber to view this report.


Recent News from (OTC: CBIS)

Cannabis Science President & CEO Mr. Raymond C. Dabney Awarded The 2018 Harvard Global Health Catalyst Industry Leader Award May 25-27th at Harvard Medical School, Boston, MA
IRVINE, CA, May 14, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that Mr. Raymond C. Dabney, the Company’s President, Chief Executive Officer (CEO), and Co-founder, has been named...
Source: GlobeNewswire
Date: May, 14 2018 07:40
Cannabis Science Announces the Second Frontiers Peer-Reviewed Publication of its Research Results on the Use of Cannabinoids in the Treatment of Cancers
IRVINE, CA, May 01, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the second publication of its research results on the use of cannabinoids (CBD’s) to treat various cancers. Th...
Source: GlobeNewswire
Date: May, 01 2018 07:44
Inspired by the Upcoming CNN Special Report, Weed: Pot Vs. Pills, by Dr. Sanjay Gupta, Cannabis Science Announces its 'Cannabis Science to End Opioid Deaths Campaign'
IRVINE, CA, April 27, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, and its partner, Cali RX, are pleased to announce the CBIS Cali RX location at 14006 Ventura Boulevard, Sherman Oaks, Califo...
Source: GlobeNewswire
Date: April, 27 2018 10:48
Cannabis Science is Proud to Announce 4/20 Success! Opening of the First CBIS Cali Rx Location on Ventura Blvd, in Sherman Oaks, California
IRVINE, CA, April 23, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, and its partner, Cali RX, are pleased to announce the soft opening of the CBIS Cali RX. The CBIS Cali RX is located at 14006 Vent...
Source: GlobeNewswire
Date: April, 23 2018 07:55
Cannabis Science Issues First 2018 Guidance Report; 4/20 Court Date Set For Lawsuit Against San Joaquin County; Revenue Growth Through Acquisitions, Wholesale, and Retail Sales Channels All Multiply
IRVINE, CA, April 10, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to issue a 2018 First Quarter Guidance Report and announces court date set for April 20, 2018 in the Company’s ...
Source: GlobeNewswire
Date: April, 10 2018 07:51
Cannabis Science, Inc. Announces Support for the Global Hemp Group and Senator Mitch Mcconnell's Hemp Legislation; CBIS Ceo Eyes 4/20 for a CBIS Pharmacy Grand Opening Party
IRVINE, CA , March 27, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it fully supports the Global Hemp Group and the Hemp Farming Act of 2018. Yesterday, Senator Mitch...
Source: GlobeNewswire
Date: March, 27 2018 13:56
Cannabis Science Acquires Bottle It Inc., State-of-the-Art 27,000 Sq. Ft., Bottling Manufacturing Facility for Various Bottled Waters, Energy Drinks, Vitamin Shots, Tincture Bottles, Sprays, and Various Sized Food Containers
IRVINE, CA, March 19, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that Cannabis Science has acquired Bottle It, Inc., located in Corona, California. Bottle It is Southern C...
Source: GlobeNewswire
Date: March, 19 2018 07:50
Cannabis Science Enters Multi-Billion USD Beverage Industry as it Partners with Crown Baus to Distribute Non-Alcohol Versions of Crown Baus' Newly Acquired Cannabia, The World's First Cannabis Beer
IRVINE, CA, March 14, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that Cannabis Science enters the multi-billion USD beverage industry as it partners with Crown Baus Capita...
Source: GlobeNewswire
Date: March, 14 2018 14:00
Cannabis Science Integrates iCannabinoid Into Pharmacy Openings, While Building, Product Manufacturing, Packaging & Cultivation Procedures are Pending CBIS and City Approvals
Grand Opening of First CBIS Pharmacies Expected Soon IRVINE, CA, March 05, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company’s first two PRE-ICO, medic...
Source: GlobeNewswire
Date: March, 05 2018 09:23
Cannabis Science Announces Beta Launch of iCannabinoid, a High-Tech, State-of-the-Art, Medical Marijuana Social Media Educational Website
IRVINE, CA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc., (OTC: CBIS) a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the beta launch of iCannabinoid, the Company’s state-of-the-art, high technology social media an...
Source: GlobeNewswire
Date: February, 27 2018 07:42


About Cannabis Science, Inc. (OTC: CBIS)

Logo for Cannabis Science, Inc. (OTC: CBIS)

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS S/BCC , CS TATI , and CS NEURO , respectively.

 

 

 

Current Management

  • Raymond Dabney / President, CEO, CoFounder
    • Mr. Raymond C. Dabney, President amp CEO, CoFounder Mr. Dabney brings years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance. Mr. Dabney has cofounded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, hightech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
  • Benjamin Tam / Secretary, CFO
  • Robert Kane / COO
    • Chief Financial Officer and Director Mr. Kane wrote his first business plan in . In , he was hired at Ryan, Beck, and Company, which was bought by the yearold, top ten, financial firm Stifel Nicolaus NYSE: SF as a registered representative. On December , , Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations. Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for Cannabiz Business University. Robert Kane s mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
  • Raymond Dabney / Chairman
    • Mr. Raymond C. Dabney, President amp CEO, CoFounder Mr. Dabney brings years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance. Mr. Dabney has cofounded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, hightech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
  • Robert Kane / Director
    • Chief Financial Officer and Director Mr. Kane wrote his first business plan in . In , he was hired at Ryan, Beck, and Company, which was bought by the yearold, top ten, financial firm Stifel Nicolaus NYSE: SF as a registered representative. On December , , Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations. Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for Cannabiz Business University. Robert Kane s mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
  • Benjamin Tam /

Current Share Structure

  • Market Cap: $143,411,458 - 05/11/2018
  • Issue and Outstanding: 2,551,805,296 - 10/16/2017
  • Float: 24,000,000 - 06/17/2010

 


Recent Filings from (OTC: CBIS)

Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 11 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 31 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 30 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 23 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: August, 15 2017
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: August, 11 2017

 


Daily Technical Chart for (OTC: CBIS)

Daily Technical Chart for (OTC: CBIS)


Stay tuned for daily updates and more on (OTC: CBIS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CBIS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBIS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of CBIS and does not buy, sell, or trade any shares of CBIS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/